{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:09:20Z","timestamp":1789834160029,"version":"4.0.1"},"reference-count":61,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardiotoxicity deals with the most common cardiovascular complications of conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation. This narrative review focuses on hematological cancer-therapy-related cardiotoxicity\u2019s definition, risk stratification, multimodality imaging, and use of cardiac biomarkers to detect clinical and\/or subclinical myocardial dysfunction and electrical instability. Moreover, the most common cardiotoxic profiles of the main drugs and\/or therapeutic interventions in patients with hematological malignancies are described thoroughly.<\/jats:p>","DOI":"10.3390\/life14040524","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T07:55:54Z","timestamp":1713426954000},"page":"524","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0223-185X","authenticated-orcid":false,"given":"Evdokia","family":"Mandala","sequence":"first","affiliation":[{"name":"Division of Hematology, Forth Department of Medicine, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8167-4765","authenticated-orcid":false,"given":"Kyranna","family":"Lafara","sequence":"additional","affiliation":[{"name":"Division of Hematology, Forth Department of Medicine, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kokkinovasilis","sequence":"additional","affiliation":[{"name":"Division of Hematology, Forth Department of Medicine, School of Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kalafatis","sequence":"additional","affiliation":[{"name":"Cardiology-Oncology Unit, Theagenion Cancer Hospital, 54639 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Koukoulitsa","sequence":"additional","affiliation":[{"name":"Cardiology-Oncology Unit, Theagenion Cancer Hospital, 54639 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-807X","authenticated-orcid":false,"given":"Eirini","family":"Katodritou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Theagenion Cancer Hospital, 54639 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0351-1319","authenticated-orcid":false,"given":"Christos","family":"Lafaras","sequence":"additional","affiliation":[{"name":"Cardiology-Oncology Unit, Theagenion Cancer Hospital, 54639 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.15420\/ecr.2022.63","article-title":"The 2022 European Society of Cardiology Cardio-oncology Guidelines in Focus","volume":"18","author":"Gent","year":"2023","journal-title":"Eur Cardiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur. Heart J.-Cardiovasc. Imaging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11864-023-01175-z","article-title":"A Comprehensive Review of Cancer Drug\u2013Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies","volume":"25","author":"Costanzo","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"792751","DOI":"10.3389\/fphys.2021.792751","article-title":"Multi-Target Drugs for Blood Cancer in the Elderly: Implications of Damage and Repair in the Cardiovascular Toxicity","volume":"12","author":"Madonna","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6616265","DOI":"10.1155\/2021\/6616265","article-title":"Assessment and Management of Cardiotoxicity in Hematologic Malignancies","volume":"2021","author":"Bojan","year":"2021","journal-title":"Dis. Markers"},{"key":"ref_7","first-page":"457","article-title":"An Overview of Cardio-Oncology, a New Frontier to Be Explored","volume":"37","author":"Cheng","year":"2021","journal-title":"Acta Cardiol. Sin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100818","DOI":"10.1016\/j.cpcardiol.2021.100818","article-title":"Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques","volume":"46","author":"Manno","year":"2021","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2217\/fca-2022-0024","article-title":"Right ventricle toxicity in cancer treatment: A focused review on cardiac imaging","volume":"19","author":"Sanadgol","year":"2023","journal-title":"Futur. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/1573403X18666220531094800","article-title":"Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review","volume":"19","author":"Madanat","year":"2023","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00259-022-05991-7","article-title":"Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: Prospects and proposal of use by the European Association of Nuclear Medicine (EANM)","volume":"50","author":"Totzeck","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11897-022-00544-3","article-title":"LVEF by Multigated Acquisition Scan Compared to Other Imaging Modalities in Cardio-Oncology: A Systematic Review","volume":"19","author":"Printezi","year":"2022","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e15226","DOI":"10.1016\/j.heliyon.2023.e15226","article-title":"Role of advanced cardiovascular imaging in chemotherapy-induced cardiotoxicity","volume":"9","author":"Cannizzaro","year":"2023","journal-title":"Heliyon"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11886-022-01641-4","article-title":"PET Tracers for Imaging Cardiac Function in Cardio-oncology","volume":"24","author":"Kelly","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11864-019-0672-z","article-title":"Advanced Imaging Modalities to Monitor for Cardiotoxicity","volume":"20","author":"Seraphim","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e013755","DOI":"10.1161\/JAHA.119.013755","article-title":"Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies","volume":"9","author":"Biersmith","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The Role of Biomarkers in Cardio-Oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11886-022-01834-x","article-title":"Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology","volume":"25","author":"Joolharzadeh","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/hon.3140","article-title":"Are we reaching the maximum cure rate for Hodgkin lymphoma?","volume":"41","author":"Johnson","year":"2023","journal-title":"Hematol Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1515\/cclm-2020-0566","article-title":"Cardiotoxic effects and myocardial injury: The search for a more precise definition of drug cardiotoxicity","volume":"59","author":"Cardinale","year":"2021","journal-title":"Clin. Chem. Lab. Med. (CCLM)"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early Detection of Anthracycline Cardiotoxicity and Improvement with Heart Failure Therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e009445","DOI":"10.1161\/CIRCHEARTFAILURE.121.009445","article-title":"Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity","volume":"15","author":"Henriksen","year":"2022","journal-title":"Circ. Heart Fail."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhou, X., Weng, Y., Jiang, T., Ou, W., Zhang, N., Dong, Q., and Tang, X. (2023). Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11060-5"},{"key":"ref_26","first-page":"34","article-title":"Lymphoma: Diagnosis and Treatment","volume":"101","author":"Lewis","year":"2020","journal-title":"Am. Fam. Physician"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Manavi, M.A., Nasab, M.H.F., Jafari, R.M., and Dehpour, A.R. (2024). Mechanisms underlying dose-limiting toxicities of conventional chemotherapeutic agents. J. Chemother., 1\u201331.","DOI":"10.1080\/1120009X.2023.2300217"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.lfs.2018.12.018","article-title":"Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision","volume":"218","author":"Iqubal","year":"2019","journal-title":"Life Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.2174\/1568026621666210813112935","article-title":"Natural Bioactive as a Potential Therapeutic Approach for the Management of Cyclophosphamide-induced Cardiotoxicity","volume":"21","author":"Iqubal","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Schmittlutz, K., and Marks, R. (2021). Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: Practical considerations for the hematologist. Ther. Adv. Hematol., 12.","DOI":"10.1177\/2040620721996484"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Molica, M., Scalzulli, E., Colafigli, G., Fo\u00e0, R., and Breccia, M. (2019). Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia. Ther. Adv. Hematol., 10.","DOI":"10.1177\/2040620719826444"},{"key":"ref_32","first-page":"79","article-title":"Cardiovascular Toxicity Associated with Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia","volume":"1","author":"Binzaid","year":"2021","journal-title":"Gulf J. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib","volume":"316","author":"Singh","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_34","first-page":"570","article-title":"Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"Cardio Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17474086.2022.2067526","article-title":"Cardiotoxicity of BTK inhibitors: Ibrutinib and beyond","volume":"15","author":"Christensen","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000528019","article-title":"Ibrutinib and Bruton\u2019s Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Focus on Atrial Fibrillation and Ventricular Tachyarrhythmias\/Sudden Cardiac Death","volume":"68","author":"Boriani","year":"2023","journal-title":"Chemotherapy"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.2147\/DDDT.S377697","article-title":"Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical","volume":"16","author":"Dong","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-019-0784-4","article-title":"Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management","volume":"21","author":"Patel","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hon.2959","article-title":"Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials","volume":"40","author":"Das","year":"2022","journal-title":"Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"193","DOI":"10.23736\/S0031-0808.20.04148-8","article-title":"Old and new generation proteasome inhibitors in multiple myeloma","volume":"62","author":"Montefusco","year":"2021","journal-title":"Panminerva Medica"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/heartjnl-2020-318748","article-title":"Optimising cardiovascular care of patients with multiple myeloma","volume":"107","author":"Oliveira","year":"2021","journal-title":"Heart"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1080\/10428194.2023.2247513","article-title":"Thrombosis in multiple myeloma: Mechanisms, risk assessment and management","volume":"64","author":"Jarchowsky","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.19017","article-title":"Direct oral anticoagulants versus aspirin for primary thromboprophylaxis in patients with multiple myeloma undergoing outpatient therapy: A systematic review and updated meta-analysis","volume":"203","author":"Costa","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40265-022-01830-z","article-title":"Diagnosis and Treatment of AL Amyloidosis","volume":"83","author":"Palladini","year":"2023","journal-title":"Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Rapezzi","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41408-021-00486-4","article-title":"Comprehensive Review of AL amyloidosis: Some practical recommendations","volume":"11","author":"Bazarbachi","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","article-title":"The Pharmacology of T Cell Therapies","volume":"8","author":"Milone","year":"2018","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Haslauer, T., Greil, R., Zaborsky, N., and Geisberger, R. (2021). CAR T-Cell Therapy in Hematological Malignancies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168996"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"663201","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions Related to CAR-T Cell Therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_52","first-page":"97","article-title":"CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"Cardio Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11864-021-00925-1","article-title":"Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment","volume":"23","author":"Bock","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/ejh.14121","article-title":"Teclistamab-cqyv in multiple myeloma","volume":"112","author":"Martino","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"103363","DOI":"10.1016\/j.retram.2022.103363","article-title":"Cardiovascular diseases in patients after hematopoietic stem cell transplantation: Systematic review and Meta-analysis","volume":"71","author":"Alizadehasl","year":"2023","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11912-019-0774-6","article-title":"Cardiac Complications in the Adult Bone Marrow Transplant Patient","volume":"21","author":"Tuzovic","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1080\/14779072.2021.2013811","article-title":"Cardiotoxicity in pediatric lymphoma survivors","volume":"19","author":"Bansal","year":"2021","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.rpor.2019.09.002","article-title":"Cardiotoxicity of mediastinal radiotherapy","volume":"24","author":"Ratosa","year":"2019","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Siaravas, K.C., Katsouras, C.S., and Sioka, C. (2023). Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076272"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/4\/524\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:29:48Z","timestamp":1760106588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/14\/4\/524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["life14040524"],"URL":"https:\/\/doi.org\/10.3390\/life14040524","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}